The menstrual health app market has never been more competitive—yet in a space long dominated by surface-level period trackers, one platform has emerged as the clear leader.
Clue, the Berlin-based, science-first reproductive health app, has officially surpassed 1 million paid subscribers, overtaking long-time rival Flo to cement its position as the most trusted, medically-backed platform in FemTech.
Founded by Ida Tin, who famously coined the term FemTech, Clue was never just about tracking cycles. From the start, it set out to close the gender health data gap—bringing together scientific research, medical partnerships, and user empowerment to deliver meaningful impact across every life stage.
Clue’s mission is bigger than periods. It’s about reproductive health intelligence.
While many apps offer generic cycle predictions, Clue stands apart by providing deeply personalised insights—spanning conception, pregnancy, perimenopause, and beyond. These insights are powered by the world’s largest reproductive health dataset, positioning Clue as the go-to app for anyone seeking more than just symptom tracking.
And it’s not just user numbers that speak to Clue’s leadership. With an industry-leading 4.8-star rating from over 2.5 million reviews, a 9.3% conversion rate, and outstanding subscriber retention, the platform has become a benchmark for trust in a space where data privacy and clinical rigour are paramount.
Clue’s success isn’t solely about scale—though doubling its paid subscriber base in a year is a milestone worth celebrating. It’s about redefining what reproductive health apps can and should be. From data ethics to medical-grade product design, Clue continues to lead the industry forward, pushing beyond basic tracking to deliver full reproductive health intelligence.
As the FemTech category continues to expand, Clue is not just keeping pace—it’s setting the standard and shaping the future.
